Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



U.S CRO Market Leverages Opportunity as Healthcare Companies Reduce R&D Budgets Finds Frost & Sullivan - CROs experience two-tiered growth with pharma and biotech companies looking to outsource - Pharma.Frost.com
U.S CRO Market Leverages Opportunity as Healthcare Companies Reduce R&D Budgets Finds Frost & Sullivan

 

PRZOOM - /newswire/ - Mountain View, CA, United States, 2011/10/13 - CROs experience two-tiered growth with pharma and biotech companies looking to outsource - Pharma.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

While the economic downturn took a toll on most markets, the U.S. contract research organization (CRO) market bucked the trend to post impressive growth rates of 8.5 percent in 2009. The slowdown in funding for early-stage projects has, no doubt, dampened the market's prospects for the next three years to four years, but this lack of funding has also restricted companies from investing in in-house clinical trials, creating opportunities for CROs.

New analysis from Frost & Sullivan's (pharma.frost.com) U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade research finds that the market earned revenues of $11.43 billion in 2010 and estimates this to reach $20.09 billion in 2017.

If you are interested in more information on this study, please send an email to Britni Myers, Corporate Communications, at britni.myers[.]frost.com, with your full name, company name, title, telephone number, company email address, company Website, city, state and country.

Market participants are optimistic about continued growth due to the interest shown by new sponsors, especially biotechnology and specialty pharmaceutical companies that are demanding full services–from the pre-clinical to post-commercialization stages. This spurt in demand and strategic partnerships with CROs could be mainly attributed to the sponsors' limited development infrastructure.

"The sponsor-CRO relationship has historically been heavily transaction-based," said a Frost & Sullivan senior research analyst. "However, in the past few years, companies have been making a gradual shift to strategic alliances that are built on a long-term view of outsourcing rather than transactions."

Earlier, start-up pharmaceutical and biotechnology companies would out-license their product after Phase I/II or acquisition, which raised a question mark over the future of projects. This trend is slowly phasing out as companies are increasingly retaining products within their pipeline and taking them closer to the market through CROs, thereby increasing the value of the products and the company. The enhanced profile of CROs, in recent times, is expected to significantly improve the market's penetrations rates.

"Despite the existence of CROs for more than two decades now, the penetration rate of outsourcing, as a percentage of the total R&D spending, is less than 25.0 percent," said the senior research analyst. "Hence, there is great potential for CROs to grow through just expansion."

Meanwhile, as trials continue to become increasingly complex and global, the competition for access to patients, new investigators, and fresh studies has started heating up. The gap between patient access and studies has been rising consistently over the past decade and could affect future studies. For studies that depend heavily on emerging markets, this patient access-study gap could lower productivity by lengthening the time for each trial.

There is also an underlying churn among existing investigators, which is causing this divide to widen further. CROs and sponsors are grappling with the situation and are exploring new ways to increase access to patients.

"CROs and service providers are looking to counter this challenge by partnering with patient recruitment firms," said the senior research analyst. "Service providers are also outsourcing large-scale global trials through the expanded reach of CRO partners, which enables access to an extensive patient pool."

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade is part of the Pharmaceuticals & Biotechnology Growth Partnership Services program, which also includes research in the following markets: U.S. Contract Research Organizations Markets, Global CRO Spending Trends, Global Biopharmaceutical Contract Manufacturing Market, and Strategic Analysis of Opportunities in the CRO Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade / N8B7

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


U.S CRO Market Leverages Opportunity as Healthcare Companies Reduce R&D Budgets Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Britni Myers 
210-477-8481 britni.myers[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com

Visit  BizJobs.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today